FDA grants orphan drug status to Bayer's bronchiectasis medicine Ciprofloxacin DPI

The US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with non-cystic fibrosis bronchiectasis (NCFB).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news